Lung Cancer

My reliable primary care physician was such an important asset in navigating multiple cancers.

Radiation plus targeted or immunotherapies could be beneficial for certain patients with lung cancer, and expert said at the CURE® Educated Patient® Lung Cancer Summit.

Patients with lung cancer may have personalized treatment options after biomarker testing, an expert said at the CURE® Educated Patient® Lung Cancer Summit.

Treatment for lung cancer has changed significantly with immunotherapy, an expert said during the CURE® Educated Patient® Lung Cancer Summit.

The Food and Drug Administration approved Augtyro for patients over the age of 12 with NTRK-positive solid tumors.

For patients with non-small lung cancer and brain metastases, it’s important to consent to shaving the scalp before tumor-treating fields therapy.

The Food and Drug Administration will speed up their review and potential approval of Tagrisso for certain patients with EGFR-mutant lung cancer.

Some patients with stage 3 non-small cell lung cancer saw benefits from Opdivo plus chemotherapy followed by surgery then Opdivo, researchers found.

I believe I have hereditary cancer, especially after my daughter was approved to receive genetic testing for breast cancer.

Dato-DXd was efficacious in patients with non-small cell lung cancer with brain metastases who have certain gene alterations, a phase 2 study showed.

Tagrisso following chemoradiotherapy improved progression-free survival compared with placebo in stage 3 EGFR-mutated non–small cell lung cancer.

Researchers found telehealth care to deliver comparable quality-of-life benefits versus in-person visits among patients with advanced non-small cell lung cancer.

For the first time in decades, a new regimen — consolidation Imfinzi after chemoradiation — improved outcomes in patients with limited-stage small cell lung cancer.

Rybrevant plus Leclaza had promising response and progression-free survival rates in patients with EGFR-mutant non-small cell lung cancer.

Rybrevant plus Leclaza outperformed Tagrisso regarding progression-free survival in patients with EGFR-mutant non-small cell lung cancer.

Lorbrena demonstrated longer progression-free survival and improved time to intracranial progression, compared with Xalkori in ALK-positive non-small cell lung cancer.

After being diagnosed with cancer, I learned that everyone handles grief differently.

When I received my diagnosis of lung cancer, I didn't want to have chemotherapy, but the doctor knew best.

Onivyde did not outperform chemotherapy in improving outcomes for patients with relapsed small cell lung cancer, despite having better response rates.

Patients with high-risk early-stage non-small cell lung cancer who underwent surgery reported similar quality of life outcomes as those who had radiation.

When it comes to high blood sugar, cancer and diabetes can create a “vicious cycle,” as one expert explained.

The Food and Drug Administration approved Imdelltra (tarlatamab) for the treatment of patients with advanced small cell lung cancer that progressed on or after a platinum-based chemotherapy.

Imfinzi should be standard of care for post-chemoradiotherapy non-small cell lung cancer treatment, but some patients are not getting the drug, a study found.

The Food and Drug Administration will speed up its review of SNB-101 to treat patients with small cell lung cancer.

The Food and Drug Administration granted a Biologics License Application for subcutaneous Opdivo for potential approval.